[Form 4] Vaxcyte, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Vaxcyte, Inc. (PCVX) insider change: Chief Operating Officer Wassil Jim reported transactions dated 09/08/2025 showing a disposition of 2,759 shares of common stock at $32.41 per share, recorded as surrendered shares to cover tax withholding on vested restricted stock units. After the reported transactions, the filing states the reporting person beneficially owned 141,848 shares. The filing also discloses a separate transfer: on 09/09/2025 the reporting person transferred 1,663 shares to an ex-spouse under a divorce settlement reflected as a domestic relations order, and those transferred shares will not be reported as beneficially owned in future Section 16 filings.

Positive

• Disclosure compliance: The Form 4 provides clear detail on the RSU tax-withholding surrender and the domestic relations transfer, supporting regulatory transparency.
• Complete ownership reporting: Post-transaction beneficial ownership (141,848 shares) is stated, aiding investor clarity.

Negative

• Insider disposition: The reporting person disposed of 2,759 shares via surrender to cover taxes, reducing direct holdings.
• Ownership reduced by domestic relations transfer: 1,663 shares were transferred to an ex-spouse and will no longer be reported as beneficially owned.

Insights

Corporate Governance Expert

TL;DR: Routine Section 16 disclosure showing share surrender for tax withholding and a domestic-relations transfer; governance and reporting appear compliant.

The Form 4 reports a common pattern where vested RSUs were used to satisfy tax withholding obligations, evidenced by the surrender of 2,759 shares at $32.41. Such transactions are generally administrative and not indicative of company-level operational changes. The additional transfer of 1,663 shares to an ex-spouse pursuant to a domestic relations order is a personal matter that reduces the reporting person’s beneficial ownership and is appropriately disclosed to maintain Section 16 transparency. Documentation appears to follow filing requirements and includes an attorney-in-fact signature.

Securities Compliance Analyst

TL;DR: Disclosure is clear and timely for insider dispositions; transactions are procedural rather than material to investors.

The filing lists transaction date 09/08/2025 and a post-transaction beneficial ownership of 141,848 shares. The code 'F' indicates a sale to cover tax withholding on RSU vesting, a common internal action. The separate transfer on 09/09/2025 under a domestic relations order was disclosed in the explanation, satisfying Section 16(a)(12) notice obligations. From a compliance perspective, the form contains the required details and signature through an attorney-in-fact, reducing regulatory risk of incomplete insider reporting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wassil Jim

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, STE. 300

(Street)

SAN CARLOS CA 94070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF OPERATING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2025		F		2,759(1)	D	$32.41	141,848(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

2. The Reporting Person entered into a divorce settlement agreement with his ex-spouse (the Settlement Agreement") pursuant to a "domestic relations order" as defined in Section 16(a)(12) of the Securities Exchange Act of 1934, as amended. On September 9, 2025, the Reporting Person transferred 1,663 shares of Vaxcyte, Inc. Common Stock to his ex-spouse pursuant to the Settlement Agreement. Accordingly, the Reporting Person will not report beneficial ownership of or dispositions of the disposed shares in future Section 16(a) filings.

Remarks:

	Jim Wassil, by /s/ Peter N. Efremenko, Attorney-In-Fact	09/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did PCVX insider Wassil Jim report on 09/08/2025?

The filing reports a disposition of 2,759 shares of Vaxcyte common stock at $32.41 per share, surrendered to cover tax withholding on vested RSUs.

How many Vaxcyte shares does the reporting person own after the reported transactions?

The Form 4 states the reporting person beneficially owned 141,848 shares following the reported transactions.

Was there any transfer of PCVX shares related to a divorce or domestic relations order?

Yes. The reporting person transferred 1,663 shares to an ex-spouse pursuant to a divorce settlement and domestic relations order on 09/09/2025.

What does transaction code 'F' mean on this Form 4?

In this filing, code F indicates a sale to satisfy tax withholding obligations resulting from the vesting of restricted stock units.

Who signed the Form 4 for Wassil Jim?

The Form 4 was signed by an attorney-in-fact, Peter N. Efremenko, on behalf of Jim, with a signature date of 09/10/2025.